PARing down EAE by Van Epps, Heather L.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
IN THIS ISSUE
256  JEM Vol. 203, No. 2, 2006
An excess of proteinase receptors in the brain aggra-
vates demyelination in multiple sclerosis (MS), sug-
gest Noorbakhsh and colleagues on   page 425  . Mice 
lacking proteinase-activated receptor-2 (PAR2), they 
show, are protected from the brain damage charac-
teristic of experimental autoimmune encephalomy-
elitis (EAE), a model of MS.
PAR2, a G protein–coupled receptor activated 
by trypsin-like serine proteases, is best known as the 
primary pain receptor in the 
peripheral nervous system. But 
this receptor is also expressed 
on smooth muscle cells in the 
gut, where it stimulates mus-
cle contraction, and on neu-
rons and glial cells in the brain, 
where it is proposed to pro-
mote cell growth and survival.
This versatile receptor can 
also help promote inflamma-
tion. Indeed, activation of 
PAR2 on skin cells triggers the 
production of inflammatory 
cytokines, and PAR2-deficient 
mice are protected against allergic dermatitis. Noor-
bakhsh and colleagues now show that PAR2 also en-
hances inflammation in the brain.
The group noted that brain tissues from both pa-
tients with MS and mice with EAE expressed higher 
than normal levels of PAR2. In mice lacking the re-
ceptor, fewer macrophages and T cells invaded the 
central nervous system, and demyelination was less 
severe—findings the authors attribute to decreased 
inflammatory cytokine production by resident glial 
cells. This finding contrasts with their earlier studies 
of HIV-associated dementia, in which PAR2 actu-
ally protected neurons against cell death.
However, in HIV-associated dementia, PAR2 
expression is selectively increased on neurons and 
promotes cell survival. In EAE, on the other hand, 
the receptor is increased on glial cells (but not neu-
rons) and promotes inflammatory gene expression.
The authors are now searching for the pro-
teases—many of which are increased during MS and 
EAE—that activate PAR2. In the meantime, they 
suggest that interfering with this receptor on glial 
cells might provide a way to limit brain degenera-
tion in patients with MS. 
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Cholesterol-lowering statin drugs, such as Lipitor and Zocor, have 
a fortuitous side effect: they ease T cell–driven autoimmune 
diseases such as multiple sclerosis (MS) and rheumatoid arthritis 
(RA). On   page 401  , Dunn and colleagues show that statins 
curb T cell activation by robbing the cells of isoprenoids, lipid 
intermediates formed during cholesterol biosynthesis.
The ability of statins to inhibit T cell proliferation has been 
appreciated for over a decade, but the mechanism was never 
fully understood. More recently, these drugs were shown to 
inhibit inflammatory T helper (Th)-1 responses and instead 
promote Th2 responses—a shift that protects mice against Th1-
driven diseases such as RA and experimental autoimmune 
encephalomyelitis (EAE), a mouse model of MS.
A study in 2002 was the first to attribute the protective effect 
of statins in autoimmunity to a decrease in isoprenoids—lipids that 
attach to small GTP-binding proteins, allowing these proteins to 
associate with the cell membrane and transmit activating signals. 
In mice, interfering with the attachment of isoprenyl groups to the 
GTPase Rho in endothelial cells prevented T cells from crossing the 
blood–brain barrier on the road to causing EAE.
Dunn and colleagues now show that a similar mechanism is 
at play in EAE-causing T cells. T cells treated with atorvastatin 
(Lipitor) proliferated less and produced lower levels of the Th1 
cytokine interferon (IFN)-γ compared with untreated cells. This 
inhibition was traced to defects in two GTP-binding proteins—
Ras and RhoA—which failed to associate with the cell membrane 
in T cells from Lipitor-treated mice, thus preventing the 
activation of downstream signaling pathways required for T cell 
proliferation and the production of IFN-γ. Adding the relevant 
isoprenoids back to Lipitor-treated T cells reversed this effect.
Statins have a similar antiproliferative effect on tumor cells, 
an observation that prompted their testing as anticancer 
therapeutics. In fact, statins appear to have few drawbacks. So 
far, the use of these drugs has not been associated with either an 
increased incidence of Th2-driven diseases, such as asthma or 
allergies, or an increased risk of viral or bacterial infections that 
normally induce a protective Th1 response. 
Statins inhibit Th1 cells by reducing the intracellular isoprenoids 
required for Ras and RhoA function.
PAR2 (brown) expression on glial cells is 
increased in patients with multiple sclerosis.
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